Optimized PD-L1 scoring of gastric cancer

BACKGROUND: PD-1/PD-L1-Immunotherapy has been approved for gastric carcinoma. PD-L1 assessment by immunohistochemistry is the principle biomarker. Are biopsies able to map the actual PD-L1 status of the entire tumor? METHODS: Whole tumor slides of 56 gastric carcinoma were analyzed to determine the...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoemig-Markiefka, Birgid, Eschbach, Jana, Scheel, Andreas H., Pamuk, Aylin, Rueschoff, Josef, Zander, Thomas, Buettner, Reinhard, Schroeder, Wolfgang, Bruns, Christiane J., Loeser, Heike, Alakus, Hakan, Quaas, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338825/
https://www.ncbi.nlm.nih.gov/pubmed/33954872
http://dx.doi.org/10.1007/s10120-021-01195-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338825/
https://www.ncbi.nlm.nih.gov/pubmed/33954872
http://dx.doi.org/10.1007/s10120-021-01195-4

Ejemplares similares